A chimeric vesiculo/alphavirus is an effective alphavirus vaccine

Anasuya Chattopadhyay, Eryu Wang, Robert Seymour, Scott Weaver, John K. Rose

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

While a large number of mosquito-transmitted alphaviruses are known to cause serious human diseases, there are no licensed vaccines that protect against alphavirus infections. The alphavirus chikungunya virus (CHIKV) has caused multiple recent outbreaks of chikungunya fever. This virus has the potential to cause a worldwide epidemic and has generated strong interest in development of a prophylactic CHIKV vaccine. We report here on the development of a potent experimental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G). These VSVΔG-CHIKV chimeras incorporated functional CHIKV glycoproteins into the viral envelope in place of VSV G. The chimeric viruses were attenuated for growth in tissue culture but could be propagated to high titers without VSV G complementation. They also generated robust neutralizing antibody and cellular immune responses to CHIKV in mice after a single dose and protected mice against CHIKV infection. VSVΔG-alphavirus chimeras could have general applicability as alphavirus vaccines.

Original languageEnglish (US)
Pages (from-to)395-402
Number of pages8
JournalJournal of Virology
Volume87
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Chikungunya virus
Alphavirus
Vaccines
Vesicular Stomatitis
vaccines
Vesiculovirus
Viruses
chimerism
Alphavirus Infections
Glycoproteins
glycoproteins
Polyproteins
viruses
Neutralizing Antibodies
Culicidae
mice
Cellular Immunity
Disease Outbreaks
neutralizing antibodies
human diseases

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. / Chattopadhyay, Anasuya; Wang, Eryu; Seymour, Robert; Weaver, Scott; Rose, John K.

In: Journal of Virology, Vol. 87, No. 1, 01.2013, p. 395-402.

Research output: Contribution to journalArticle

Chattopadhyay, Anasuya ; Wang, Eryu ; Seymour, Robert ; Weaver, Scott ; Rose, John K. / A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. In: Journal of Virology. 2013 ; Vol. 87, No. 1. pp. 395-402.
@article{e9afad3a15544e0f986fd74cf2aff7c2,
title = "A chimeric vesiculo/alphavirus is an effective alphavirus vaccine",
abstract = "While a large number of mosquito-transmitted alphaviruses are known to cause serious human diseases, there are no licensed vaccines that protect against alphavirus infections. The alphavirus chikungunya virus (CHIKV) has caused multiple recent outbreaks of chikungunya fever. This virus has the potential to cause a worldwide epidemic and has generated strong interest in development of a prophylactic CHIKV vaccine. We report here on the development of a potent experimental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G). These VSVΔG-CHIKV chimeras incorporated functional CHIKV glycoproteins into the viral envelope in place of VSV G. The chimeric viruses were attenuated for growth in tissue culture but could be propagated to high titers without VSV G complementation. They also generated robust neutralizing antibody and cellular immune responses to CHIKV in mice after a single dose and protected mice against CHIKV infection. VSVΔG-alphavirus chimeras could have general applicability as alphavirus vaccines.",
author = "Anasuya Chattopadhyay and Eryu Wang and Robert Seymour and Scott Weaver and Rose, {John K.}",
year = "2013",
month = "1",
doi = "10.1128/JVI.01860-12",
language = "English (US)",
volume = "87",
pages = "395--402",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - A chimeric vesiculo/alphavirus is an effective alphavirus vaccine

AU - Chattopadhyay, Anasuya

AU - Wang, Eryu

AU - Seymour, Robert

AU - Weaver, Scott

AU - Rose, John K.

PY - 2013/1

Y1 - 2013/1

N2 - While a large number of mosquito-transmitted alphaviruses are known to cause serious human diseases, there are no licensed vaccines that protect against alphavirus infections. The alphavirus chikungunya virus (CHIKV) has caused multiple recent outbreaks of chikungunya fever. This virus has the potential to cause a worldwide epidemic and has generated strong interest in development of a prophylactic CHIKV vaccine. We report here on the development of a potent experimental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G). These VSVΔG-CHIKV chimeras incorporated functional CHIKV glycoproteins into the viral envelope in place of VSV G. The chimeric viruses were attenuated for growth in tissue culture but could be propagated to high titers without VSV G complementation. They also generated robust neutralizing antibody and cellular immune responses to CHIKV in mice after a single dose and protected mice against CHIKV infection. VSVΔG-alphavirus chimeras could have general applicability as alphavirus vaccines.

AB - While a large number of mosquito-transmitted alphaviruses are known to cause serious human diseases, there are no licensed vaccines that protect against alphavirus infections. The alphavirus chikungunya virus (CHIKV) has caused multiple recent outbreaks of chikungunya fever. This virus has the potential to cause a worldwide epidemic and has generated strong interest in development of a prophylactic CHIKV vaccine. We report here on the development of a potent experimental vaccine for CHIKV based on a chimeric vesicular stomatitis virus (VSV) expressing the entire CHIKV envelope polyprotein (E3-E2-6K-E1) in place of the VSV glycoprotein (G). These VSVΔG-CHIKV chimeras incorporated functional CHIKV glycoproteins into the viral envelope in place of VSV G. The chimeric viruses were attenuated for growth in tissue culture but could be propagated to high titers without VSV G complementation. They also generated robust neutralizing antibody and cellular immune responses to CHIKV in mice after a single dose and protected mice against CHIKV infection. VSVΔG-alphavirus chimeras could have general applicability as alphavirus vaccines.

UR - http://www.scopus.com/inward/record.url?scp=84871961473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871961473&partnerID=8YFLogxK

U2 - 10.1128/JVI.01860-12

DO - 10.1128/JVI.01860-12

M3 - Article

C2 - 23077320

AN - SCOPUS:84871961473

VL - 87

SP - 395

EP - 402

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 1

ER -